Biocytogen Pharmaceuticals and CtM Biotech have entered into a collaboration agreement to co-develop TCR-mimic antibody-based multi-specific T cell engagers targeting intracellular tumor-associated antigens.
Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.
Ardelyx and its Japanese collaboration partner Kyowa Kirin have amended their license agreement for tenapanor.
Biopharmaceutical firm Harbour BioMed (HBM) and AstraZeneca have entered into a global out-license agreement for CLDN18.2xCD3 bispecific antibody HBM7022.
The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for Shanghai Junshi Biosciences’ anti-CD112R monoclonal antibody (TAB009/JS009) to treat advanced solid tumours.
Women’s healthcare firm Organon has signed an agreement with Daré Bioscience for latter's Xaciato (clindamycin phosphate vaginal gel, 2%).
LifeMine Therapeutics has raised $175m in a Series C financing to advance Avatar-Rx, its evolutionarily derived genomic drug discovery platform.
Biotechnology firm Affini-T Therapeutics has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.
Triumvira Immunologics has completed an extension of Series A financing, which brings the total round to nearly $100m, for supporting the continued preclinical and clinical development of its T cell Antigen Coupler (TAC)-T cell therapy programmes.
Sanofi has announced a collaboration with investment management firm Blackstone to advance an innovative treatment for multiple myeloma.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.